Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635605 | 1.00 | MAPK1 (0.56) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL27652773 | 0.85 | MAPK1 (0.50) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL4341886 | 0.84 | MAPK1 (0.67) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL4340576 | 0.82 | MAPK1 (0.64) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL4336588 | 0.82 | MAPK1 (0.64) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL4332969 | 0.82 | MAPK1 (0.64) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL4340573 | 0.80 | MAPK1 (0.62) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL4302034 | 0.79 | KCNN4 (0.52) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL30038214 | 0.79 | KCNN4 (0.52) | MAPK1NPC1KDM4EALDH1A1MAPT | |
| SCHEMBL121866 | 0.79 | ADRA1A (0.50) | MAPK1NPC1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4543861-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-113226321-B | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| CN-101006061-A | 1,5-diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2007-07-25 | — | — | CN | disclosed |
| EP-0058841-B1 | PHENYLPYRAZOLE COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1984-12-12 | — | — | EP | disclosed |
| EP-0103030-A1 | Polycyclic fused pyrazole compounds, useful as anti-inflammatory agents, and preparation thereof | STERLING DRUG INC. (US) | 1984-03-21 | — | — | EP | disclosed |
| EP-0102404-A1 | Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof | STERLING DRUG INC. (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4412995-A | Pentacyclic phenylpyrazole compounds as anti-inflammatory agents | STERLING DRUG INC. (US) | 1983-11-01 | — | — | US | disclosed |
| US-4349559-A | Anti-inflammatory spiro-2H-indene-[2,3']-3H-pyrazolo[4\",5\":7',6']naphtho[2,1-b]pyran-1,3-dione derivatives | STERLING DRUG INC. (US) | 1982-09-14 | — | — | US | disclosed |
| US-4349558-A | Anti-inflammatory 8H-phenanthro-[2,3-c]pyrazole derivatives | STERLING DRUG INC. (US) | 1982-09-14 | — | — | US | disclosed |
| EP-0058841-A2 | Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof | STERLING DRUG INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4307102-A | Phenanthro[2,3-c]pyrazole | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | MAPK1 1871/4885NPC1 379/4885KDM4E 2829/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | MAPK1 2429/4885NPC1 642/4885KDM4E 4198/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | MAPK1 3241/4885NPC1 251/4885KDM4E 4809/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | MAPK1 2004/4885NPC1 123/4885KDM4E 2133/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | MAPK1 1203/4885NPC1 343/4885KDM4E 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.